Ratings Nxera Pharma Co., Ltd. OTC Markets

Equities

SOLTF

JP3431300007

Market Closed - OTC Markets Other stock markets 12:20:04 2024-06-20 EDT			5-day change	1st Jan Change
9.43 ^USD	-5.70%		-.--%	-5.70%

06-27	Nxera Pharma Co Achieves Key R&D Milestone in Collaboration with AbbVie; Secures $10 Million Payment	MT
06-27	Nxera Pharma Co., Ltd. Receives USD 10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

The company has insufficient levels of profitability.
The group shows a rather high level of debt in proportion to its EBITDA.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 60.48 times its estimated earnings per share for the ongoing year.
The company's enterprise value to sales, at 4.33 times its current sales, is high.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
NXERA PHARMA CO., LTD.	-5.70%	896M	-
CSL LIMITED	+2.08%	95.18B	A-
SAMSUNG BIOLOGICS CO.,LTD.	-0.13%	37.55B	A-
BIOGEN INC.	-10.43%	33.75B	B-
UCB	+77.76%	28.2B	A
BIOMARIN PHARMACEUTICAL INC.	-14.82%	15.63B	C
INCYTE CORPORATION	-3.06%	13.63B	B-
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.76%	11.5B	D+
ALTEOGEN INC.	+181.73%	10.81B	D
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-53.92%	9.23B	B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes